Hims & Hers Health went from hair loss pills to healthcare disruptor in four years. The telehealth platform that started treating erectile dysfunction and thinning hair now serves 2.47 million subscribers across weight loss, mental health, dermatology, and primary care. Revenue hit $599 million in Q3 2025 alone, up 49% year-over-year. But the stock tells a more volatile story: a February 2025 peak near $73, a 40% crash after Novo Nordisk terminated their GLP-1 partnership, and ongoing regulatory questions about compounded semaglutide.
For traders, HIMS represents a high-beta play on telehealth disruption meeting pharmaceutical industry resistance. The company’s personalized medicine model threatens traditional healthcare economics, which is exactly why it attracts both aggressive bulls and skeptical shorts.
HIMS Stock Snapshot
Technical Signal Dashboard
Real-time buy/sell signals based on 26 technical indicators including oscillators and moving averages:
HIMS Live Chart
The GLP-1 Rollercoaster: What Traders Need to Know
HIMS became a meme stock darling in 2024 when it started offering compounded semaglutide, the active ingredient in Ozempic and Wegovy, at a fraction of branded drug prices. Revenue growth exploded. The stock surged 172% in 2024 alone.
Then reality intervened. The FDA declared semaglutide shortages resolved in February 2025, threatening the legal basis for compounded alternatives. Novo Nordisk terminated their partnership in June 2025, triggering a 30-35% single-day crash. Class-action lawsuits followed. FTC scrutiny over advertising practices mounted.
The company pivoted fast. CEO Andrew Dudum shifted focus to personalized oral medications, liraglutide (a daily injectable with different regulatory status), and branded GLP-1s like Eli Lilly’s Zepbound and Mounjaro at $1,899/month. The Novo Nordisk price war continues reshaping the competitive landscape, with Wegovy and Ozempic cash prices dropping from $499 to $349 monthly.
For position traders, the GLP-1 narrative creates predictable volatility patterns. FDA announcements, Novo Nordisk pricing moves, and quarterly subscriber numbers all trigger outsized price swings. The stock’s beta of 2.01 confirms what the chart shows: HIMS moves twice as much as the market in either direction.
HIMS Fundamental Data
Key financial metrics updated in real-time:
Understanding the Business Model
Hims & Hers operates a vertically integrated telehealth platform connecting patients to licensed providers, cloud pharmacy fulfillment, and personalized treatment protocols. The model disrupts traditional healthcare by eliminating waiting rooms, insurance paperwork, and in-person appointments for conditions patients often find embarrassing to discuss.
Revenue breakdown (Q3 2025): The company generated $599 million quarterly revenue with 2.47 million subscribers paying an average of $80/month. Personalized treatment subscribers hit 1.6 million, representing 65% of the customer base and driving higher retention rates. The weight loss category alone is projected to generate $725 million in 2025 revenue.
Geographic expansion: Beyond its U.S. base, HIMS acquired Livewell to enter Canada and Zava to access 200 million adults across the UK, Germany, France, Ireland, and Spain. International revenue remains early-stage but represents management’s path to the ambitious $6.5 billion revenue target by 2030.
Margin dynamics: Gross margins compressed to 74% in Q3 2025 (down 500 basis points YoY) as the company shifted weight loss fulfillment to smaller shipment cadences. Management expects $20-25 million in headwinds from this transition in Q4, normalizing by H2 2026. Adjusted EBITDA margins run around 13% with a path to 20% at scale.
Company Profile
Key Trading Levels and Technical Patterns
52-week range: $23.97 to $72.98. The stock currently trades near the lower third of this range, roughly 50% below February 2025 highs. For swing traders, the $32-34 zone has established support through multiple tests in November and December 2025.
Moving average dynamics: The 100-day moving average recently crossed below the 200-day MA, a traditionally bearish signal. However, a similar pattern in 2023 preceded a major rally when accompanied by RSI bullish divergence. Watch for confirmation before assuming direction.
Volume patterns: Average daily volume runs 10-11 million shares, but spikes to 20-30 million on news catalysts. The stock responds dramatically to FDA announcements, earnings reports, and GLP-1 pricing news from competitors. Position sizing should account for these volatility events.
Analyst targets: Wall Street maintains a consensus hold rating with an average price target around $44-48, implying 30-40% upside from current levels. The range spans from Bank of America’s $32 underperform to bulls targeting $68-85. This wide dispersion reflects genuine uncertainty about regulatory outcomes and competitive positioning.
HIMS News Feed
Latest headlines and market-moving developments:
Bull Case vs. Bear Case
Bulls argue: Hims & Hers is building the “Amazon of healthcare,” a consumer-first platform that makes personalized medicine accessible and affordable. Subscriber growth remains strong despite GLP-1 headwinds. The personalized treatment model creates switching costs and higher lifetime value. International expansion opens massive new markets. At 60x trailing earnings, the premium reflects 50%+ revenue growth, not overvaluation.
Bears counter: The company depends too heavily on GLP-1 weight loss products facing regulatory and competitive pressure. Gross margins are compressing. Novo Nordisk’s price cuts squeeze the value proposition for compounded alternatives. FTC advertising scrutiny and class-action lawsuits create headline risk. The stock trades at 3x sales for a company that may face structural headwinds to its fastest-growing business line.
The balanced view: HIMS represents a binary bet on telehealth disruption. The business model works, subscriber economics are strong, and management has shown adaptability. But the GLP-1 regulatory situation remains unresolved, and pharmaceutical giants have deep pockets to compete on price. Position accordingly.
Trading HIMS: Strategies and Considerations
Event-driven approaches: The stock’s high beta and news sensitivity create opportunities around known catalysts. Earnings reports (next: March 2, 2026), FDA regulatory announcements, and competitor pricing moves all generate predictable volatility. Options premiums reflect this, with implied volatility typically elevated around these dates.
Momentum trading: HIMS tends to trend rather than mean-revert. The stock spent months above $50 before the June crash, then months below $40 afterward. Breakouts from consolidation ranges often extend further than expected in both directions.
Risk management: With a beta above 2.0, standard position sizing rules may underestimate actual portfolio impact. Consider reducing position size by 50% compared to lower-volatility names. Stop losses should account for the stock’s tendency to gap on news.
Institutional activity: The company completed a $250 million share buyback authorization in November 2025, providing some price support. Hedge funds have been net sellers in recent months according to 13F filings, though new institutional buyers continue to emerge.
Related Healthcare and Growth Stocks
Frequently Asked Questions
What does Hims & Hers Health do?
Hims & Hers operates a telehealth platform connecting patients to licensed healthcare providers for personalized treatment across sexual health, hair loss, mental health, skincare, weight loss, and primary care. The company handles everything from online consultations to prescription fulfillment and ongoing care management.
Why did HIMS stock crash in 2025?
The stock dropped 40%+ from its February 2025 peak of $73 after two major events: the FDA declaring semaglutide shortages resolved (threatening compounded GLP-1 sales) and Novo Nordisk terminating their Wegovy partnership in June 2025. Regulatory uncertainty and competitive pressure from pharmaceutical giants triggered the selloff.
Is HIMS stock a buy right now?
Analyst opinions are mixed. The consensus rating is hold with an average price target around $44-48, implying significant upside. Bulls point to strong subscriber growth and diversification beyond GLP-1s. Bears worry about regulatory headwinds and margin compression. The stock’s high volatility makes it more suitable for traders who can stomach 20%+ swings than conservative investors.
What is HIMS stock’s market cap?
Hims & Hers has a market capitalization around $7.5-8 billion as of late December 2025, with approximately 228 million shares outstanding. The company trades on the New York Stock Exchange under ticker HIMS.
Does HIMS pay a dividend?
No. Hims & Hers does not pay dividends. The company reinvests cash flow into growth initiatives including international expansion, new product development, and infrastructure. Management has authorized share buybacks as an alternative form of capital return.
When does HIMS report earnings?
The next earnings report is scheduled for March 2, 2026 covering Q4 2025 results. The company typically reports after market close and hosts a conference call for analysts and investors.
What is HIMS stock’s P/E ratio?
HIMS trades at approximately 60-63x trailing earnings, well above the market average of 17x. The premium valuation reflects expectations for continued 50%+ revenue growth and improving profitability as the business scales.
Who are HIMS competitors?
Direct telehealth competitors include Teladoc Health (TDOC), Ro, and Nurx. In weight loss specifically, HIMS competes with pharmaceutical giants Novo Nordisk (NVO) and Eli Lilly (LLY), as well as other compounding pharmacies and weight loss clinics. The company’s broader vision positions it against traditional healthcare providers and pharmacy benefit managers.
Trading Tools and Related Charts
Track related assets and market context with these BusinessTech.News resources:
- VIX Live Chart – Monitor market volatility and fear levels
- PLTR Live Chart – Another high-growth, high-beta tech name
- NFLX Live Chart – Subscription business model comparison
- META Live Chart – Large-cap growth stock dynamics
This page provides real-time data for informational purposes. HIMS stock involves significant volatility and regulatory risk. Conduct thorough research and consider your risk tolerance before trading. Past performance does not guarantee future results.